11:43 AM EST - Awakn Life Sciences : Announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd., one of the largest publicly listed U.S. based ketamine wellness-clinic chains. The agreement will enable Revitalist to treat clients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUd, Alcohol Use Disorder. The U.S. alcohol and substance addiction treatment industry is significant with 14,000+ treatment facilities across the country generating more than $35bn in revenue. Awakn aims to improve performance of this industry by providing clinic operators with access to an efficient and effective treatment option under license. Awakn Life Sciences
shares N.AWKN are trading up $0.05 at $0.58.
